May 21, 2021
Transcatheter therapies for tricuspid valve disease continue to gain momentum, as evidenced by three studies presented at this week’s EuroPCR 2021: TRISCEND, TriBAND, and CLASP TR.
On the whole, the early data suggest these devices are a viable treatment for tricuspid regurgitation (TR), investigators told the meeting’s virtual audience, yet they also speak to the diverse approaches annular reduction, transcatheter edge-to-edge repair (TEER), and valve replacement aimed at addressing this clinical niche.
All three are manufactured by Edwards Lifesciences:
Thirty-day data from TRISCEND make the case for valve replacement, specifically with the Evoque device, in patients with symptomatic and at least moderate TR.
January 26, 2021
A new risk score based on machine learning shows promise in predicting death, MI, and bleeding following an ACS event, potentially allowing clinicians to better individualize care.
The score, called PRAISE, is not the first score proposed to aide in outcome prediction and dual antiplatelet therapy (DAPT) duration decisions for this cohort of patients; one specifically designed for use in patients at high bleeding risk was published just last week. But the machine learning component is novel.
“The study showed that a machine learning approach is feasible and effective and more accurate than currently existing predictive scores that are based upon conventional and classical statistical methods,” study co-author Ovidio De Filippo, MD (University of Turin, Italy), told TCTMD. “We believe that this is an important step toward personalizing and having a tailored approach for patients suffering from acute coronary syndrome in order to predict their risk of death in